You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

243 Results
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
exemestane,
palbociclib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Document
Nov 2018
Document
Nov 2018
Guidelines and Advice
Status: Current
ID: PET 19
Version: n/a
Nov 2018
Guidelines and Advice
Status: In-Review
ID: 7-14
Version: 3
Dec 1969
Guidelines and Advice
Status: Current
ID: ES SMG-3
Jan 2019
Guidelines and Advice
Status: Current
ID: N/A
Version: Final
Dec 1969
Last updated: April 30, 2019 The following information identifies errors and corrections in the Ontario Cancer Statistics 2018 report and supporting...
Mar 2019
Document
Dec 1969
Guidelines and Advice
Status: Current
Mar 2019
Document
Dec 1969

Pages